Here is the design of a clinical trial:

Official Title: Randomized Open Pilot Study to Evaluate the Efficacy of Subcutaneous Sarilumab in Patients With Moderate-severe COVID-19 Infection

Included conditions:
- Covid-19

Study Armgroups:
- {'label': 'Sarilumab plus standard of care', 'type': 'EXPERIMENTAL', 'description': 'Sarilumab 200 mg, 2 sc injections in pre-filled syringe or pen, single dose. Treatment with drugs or procedures in routine clinical practice that the clinician responsible for the patient deems necessary is allowed', 'interventionNames': ['Drug: Sarilumab']}
- {'label': 'Standard of care', 'type': 'ACTIVE_COMPARATOR', 'description': 'Treatment with drugs or procedures in routine clinical practice', 'interventionNames': ['Other: Standar of care']}

Interventions:
- {'type': 'DRUG', 'name': 'Sarilumab', 'description': 'Single dose treatment with sarilumab 2 x 200 mg subcutaneously', 'armGroupLabels': ['Sarilumab plus standard of care'], 'otherNames': ['Kevzara', 'SAR153191']}
- {'type': 'OTHER', 'name': 'Standar of care', 'description': 'Usual clinical care', 'armGroupLabels': ['Standard of care']}

Primary Outcomes:
- {'measure': 'Mean change in clinical status assessment using the 7-point ordinal scale at day 7 after randomisation', 'description': 'Score ranges 1-7\n\n1. Death;\n2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO);\n3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices;\n4. Hospitalized, requiring supplemental oxygen;\n5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise)\n6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care\n7. Not hospitalized', 'timeFrame': '7 days from enrolment'}
- {'measure': 'Duration of hospitalisation (days)', 'description': 'Days from the date of enrolment to the date of discharge', 'timeFrame': '30 days from enrolment'}
- {'measure': 'Death', 'description': 'Number of deaths', 'timeFrame': '30 days from enrolment'}

Please estimate the sample size based on the assumption: 
Not explicitly stated in the provided paragraph.
Numbers to be randomised (sample size)
          30 patients treated by COVID-19 infection who require hospitalisation: 20 will receive sarilumab plus Standard of Care and 10 will receive Standard of Care.